GoPubMed Proteins lists recent and important papers and reviews for
proteins. Page last changed on 14 Mar 2013.
Mechanistic target of rapamycin
mTOR, FRAP
The protein encoded by this gene belongs to a family of phosphatidylinositol kinase-related kinases. These kinases mediate cellular responses to stresses such as DNA damage and nutrient deprivation. This protein acts as the target for the cell-cycle arrest and immunosuppressive effects of the FKBP12-rapamycin complex. The ANGPTL7 gene is located in an intron of this gene. [provided by RefSeq, Sep 2008] (from
NCBI)
Sponsored links
Papers using
mTOR
antibodies
Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth
Supplier
In Cell Cycle, 2010
Bioengineering approaches to study multidrug resistance in tumor cells
Supplier
In PLoS ONE, 2010
... , a PI3K and mTOR inhibitor was purchased from Cayman Chemical (Ann Arbor, MI).
ADP mediates inhibition of insulin secretion by activation of P2Y13 receptors in mice.
Supplier
In PLoS ONE, 2009
Cytoprotective effect of polypeptide from Chlamys farreri on neuroblastoma (SH-SY5Y) cells following HO exposure involves scavenging ROS and inhibition JNK phosphorylation.
Supplier
In PLoS ONE, 2008
... monoclonal antibodies to HIF-1α, mTOR and β-actin as well as rabbit polyclonal antibody against phospho-S2448 mTOR were from Abcam (Cambridge, UK) ...
Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway
more suppliersSupplier
In PLoS ONE, 2008
Papers on
mTOR
Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.
New
Boston, United States. In Cancer Chemother Pharmacol, 09 Apr 2013
Because of potential synergy between VEGF pathway and mTOR inhibitors, we performed a phase I study to evaluate the safety and feasibility of combining sorafenib and everolimus in patients with advanced NET.
Growth inhibition of pancreatic cancer cells by Histone Deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
New
Singapore, Singapore. In Mol Carcinog, 08 Apr 2013
Belinostat prominently inhibited PI3K-mTOR-4EBP1 signaling with a 50% suppression of phorphorylated 4EBP1 (AsPc1, BxPc3, Panc0327, Panc1005 cells).
SMC condensation centres in Bacillus subtilis are dynamic structures.
New
Freiburg, Germany. In J Bacteriol, 08 Apr 2013
Using FRAP (fluorescence recovery after photobleaching), we provide evidence that the SMC complex has high exchange rates.
Duration of rapamycin treatment has differential effects on metabolism in mice.
New
Impact
Springfield, United States. In Cell Metab, 05 Apr 2013
In the first robust demonstration of pharmacologically-induced life extension in mammals, longevity was extended in mice treated with rapamycin, an inhibitor of mechanistic TOR (mTOR).
Amino acid signalling upstream of mTOR.
New
Impact
San Diego, United States. In Nat Rev Mol Cell Biol, 31 Mar 2013
Mammalian target of rapamycin (mTOR) is a conserved Ser/Thr kinase that is part of mTOR complex 1 (mTORC1), a master regulator that couples amino acid availability to cell growth and autophagy.
Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1.
New
Impact
Boston, United States. In Science, 21 Mar 2013
The mechanistic target of rapamycin complex 1 (mTORC1) is a protein kinase that senses growth signals to regulate anabolic growth and proliferation.
Quantitative Phosphoproteomics Reveal mTORC1 Activates de Novo Pyrimidine Synthesis.
New
Impact
Basel, Switzerland. In Science, 21 Mar 2013
The Ser-Thr kinase mammalian target of rapamycin (mTOR) controls cell growth and metabolism by stimulating glycolysis and synthesis of proteins and lipids.
Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
New
Seoul, South Korea. In Int J Cancer, 07 Mar 2013
In addition, PIK3CA mutations commonly coexist with KRAS mutations and lead to additive activation of the PI3K/MTOR signaling pathway.
Which drug, and when, for patients with BRAF-mutant melanoma?
New
Impact
Washington, D.C., United States. In Lancet Oncol, 28 Feb 2013
Multiple resistance mechanisms have been identified, including those that lead to reactivation of the MAPK pathway and other pathways, such as the PI3K-AKT-mTOR and VEGF pathways.
mTOR is a key modulator of ageing and age-related disease.
Review
New
Impact
Seattle, United States. In Nature, 17 Feb 2013
A leading target for such interventions is the nutrient response pathway defined by the mechanistic target of rapamycin (mTOR).
The multi-functional roles of GNMT in toxicology and cancer.
Review
New
Taipei, Taiwan. In Toxicol Appl Pharmacol, Feb 2013
These studies suggest that GNMT not only is involved in mTOR signaling pathway, but also plays an important role in the intracellular trafficking of cholesterol.
Molecular basis of physiological heart growth: fundamental concepts and new players.
Review
New
Impact
Cincinnati, United States. In Nat Rev Mol Cell Biol, Jan 2013
Physiological hypertrophy is initiated by finite signals, which include growth hormones (such as thyroid hormone, insulin, insulin-like growth factor 1 and vascular endothelial growth factor) and mechanical forces that converge on a limited number of intracellular signalling pathways (such as PI3K, AKT, AMP-activated protein kinase and mTOR) to affect gene transcription, protein translation and metabolism.
Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis.
Review
New
München, Germany. In Transplantation, Jan 2013
Experimental and clinical data suggest that mTOR inhibitors may have an anti-CMV effect.
Rapamycin Inhibits ALDH Activity, Resistance to Oxidative Stress, and Metastatic Potential in Murine Osteosarcoma Cells.
New
Pittsburgh, United States. In Sarcoma, Dec 2012
Using this experimental system, the mammalian target of rapamycin (mTOR) pathway has been implicated in OS metastasis.
[Predictive biomarkers for anti-EGFR antibodies].
Review
New
Chiba, Japan. In Gan To Kagaku Ryoho, Nov 2012
These facts suggest that additional activating mutations in the RAS-RAF-MAPK or PI3K-AKT-mTOR pathways may also confer resistance to anti-EGFR antibody therapies.
Leucine and arginine regulate trophoblast motility through mTOR-dependent and independent pathways in the preimplantation mouse embryo.
New
GeneRIF
Charlottesville, United States. In Dev Biol, Feb 2012
These results suggest that there are two separate uterine signals regulating implantation, one that primes the embryo for the attachment reaction and another that activates mTOR and initiates invasive behavior.
The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.
GeneRIF
Columbia, United States. In Am J Physiol Heart Circ Physiol, 2012
Studies establish a role for mTOR signaling in hypertrophic cardiomyopathy caused by Q510E-Shp2 mutation.
TSC1/TSC2 inactivation inhibits AKT through mTORC1-dependent up-regulation of STAT3-PTEN cascade.
GeneRIF
Beijing, China. In Cancer Lett, 2012
mTORC1 plays role in up-regulation of STAT3-PTEN cascade
Heightened uterine mammalian target of rapamycin complex 1 (mTORC1) signaling provokes preterm birth in mice.
GeneRIF
Cincinnati, United States. In Proc Natl Acad Sci U S A, 2011
role of mTORC1 signaling in determining the timing of birth in mice may help us better understand the mechanism of the timing of birth in humans and develop new and improved strategies to combat the global problem of preterm birth
Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways.
More papers using
mTOR
antibodies
GeneRIF
Hamilton, Canada. In Radiat Oncol, 2010
AMPK, Akt and mTOR pathways have roles in resveratrol-enhanced prostate cancer cell response to ionizing radiation
Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death
Supplier
In Cell Death & Disease, 2008
... , mTOR, S6 ribosomal antibodies were from Cell Signaling (Berverly, MA, USA) ...
Endocytosis machinery is required for beta1-adrenergic receptor-induced hypertrophy in neonatal rat cardiac myocytes.
Supplier
In PLoS ONE, 2007
Macrophages promote muscle membrane repair and muscle fibre growth and regeneration during modified muscle loading in mice in vivo
Supplier
In Biochimie, 2006
Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN.
Supplier
In PLoS ONE, 2005
... (Ser-473 and Thr-308), phospho-S6 kinase (Thr-389), phospho-tuberin (Thr-1462), phospho-mTOR (Ser-2448), phospho-p65 (Ser-536), Akt, S6 kinase, mTOR and tuberin were purchased from Cell Signaling, Boston, MA ...
The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions.
Supplier
In PLoS ONE, 2005
... Polyclonal anti-mTOR antibody was from Abcam (Cambridge, MA) ...
Aerosol delivery of glucosylated polyethylenimine/phosphatase and tensin homologue deleted on chromosome 10 complex suppresses Akt downstream pathways in the lung of K-ras null mice.
Supplier
In PLoS ONE, 2003
TNF-alpha–accelerated apoptosis abrogates ANCA-mediated neutrophil respiratory burst by a caspase-dependent mechanism.
Supplier
In PLoS ONE, 2001
... IPs were performed with 6 µg of mTOR (Santa Cruz), Rictor or Raptor (Bethyl), or control goat (Santa ...
